Please use this identifier to cite or link to this item:
https://doi.org/10.1111/j.1399-0039.2011.01796.x
DC Field | Value | |
---|---|---|
dc.title | Natural killer cell engineering for cellular therapy of cancer | |
dc.contributor.author | Shook, D.R. | |
dc.contributor.author | Campana, D. | |
dc.date.accessioned | 2016-10-22T07:46:28Z | |
dc.date.available | 2016-10-22T07:46:28Z | |
dc.date.issued | 2011-12 | |
dc.identifier.citation | Shook, D.R., Campana, D. (2011-12). Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 78 (6) : 409-415. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1399-0039.2011.01796.x | |
dc.identifier.issn | 00012815 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/128979 | |
dc.description.abstract | Natural killer (NK) cells can kill transformed cells and represent a promising tool for the treatment of cancer. Their function is governed by a balance of stimulatory and inhibitory signals triggered by surface receptors. Advances in NK cell therapy require the development of dependable methods for obtaining an adequate number of effector cells; additional activation or genetic modification may further increase their anticancer capacity. A method for NK cell expansion used in our laboratory relies on a genetically modified form of the K562 myeloid leukemia cell line, engineered to express a membrane-bound form of interleukin-15 and the ligand for the costimulatory molecule 4-1BB (CD137). Expanded NK cells can be transduced with genes encoding chimeric antigen receptors that stimulate tumor cell-specific cytotoxicity. These methods for NK cell expansion and genetic modification have been adapted to large-scale, clinical-grade, Current Good Manufacturing Practice conditions and support two active clinical trials. Summarized are current efforts for NK cell immunotherapy for cancer and future perspectives. © 2011 John Wiley & Sons A/S. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1111/j.1399-0039.2011.01796.x | |
dc.source | Scopus | |
dc.subject | Cell therapy | |
dc.subject | Chimeric receptors | |
dc.subject | Immunotherapy | |
dc.subject | Natural killer cells | |
dc.type | Review | |
dc.contributor.department | PAEDIATRICS | |
dc.description.doi | 10.1111/j.1399-0039.2011.01796.x | |
dc.description.sourcetitle | Tissue Antigens | |
dc.description.volume | 78 | |
dc.description.issue | 6 | |
dc.description.page | 409-415 | |
dc.description.coden | TSANA | |
dc.identifier.isiut | 000297571200001 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.